Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014

Nerviano, Italy – October 28, 2014 – Nerviano Medical Sciences announces that results from a single-arm Phase II study of Milciclib in patients with thymic carcinoma and thymoma were disclosed in a poster discussion session at the XVI Congresso Nazionale AIOM, October 24-26, 2014, Rome, Italy.

This clinical trial represents collaborative work of Nerviano Medical Sciences with leading cancer research institutions: Istitute Gustave Roussy, Villejuif, France; Fondazione IRCSS Istituto Nazionale Tumori, Milano, Italy; National Cancer Institute, Bethesda, US; Azienda Ospedaliero-Universitaria S. Luigi Gonzaga, Orbassano, Torino, Italy; Centre hospitalier universitaire de Toulouse, Toulose, France; Cancer Treatment Centers of America, US and Georgetown University, Washington, US.

Milciclib is an inhibitor of cyclin-dependent and Src kinase family members, as well as of a limited number of additional kinases, and it was discovered by Nerviano Medical Sciences.
Thymic carcinoma (TC) and thymoma (B3 type, B3T) are rare malignant tumors of the thymus with a high unmet medical need.

Milciclib showed promising preliminary activity in TC/B3T and a well tolerated safety profile. The data so far collected support its full investigation as potential new therapeutic agent to treat TC/B3T.

Presentation title: A Phase II study of Milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC)
Authors: Besse, B Garassino, M et al.
Meeting: XVI Congresso Nazionale AIOM , 24-26 October 2014
Abstract No: D04
Sessione educazionale 3: Tumore del Polmone
Time: Saturday, 25 October

Link to the conference website: http://congresso.aiom.it/

































Per offrirti un'esperienza di navigazione ottimizzata NMS Group e le società controllate utilizzano cookies, anche di terze parti.
Proseguendo con la navigazione acconsenti al loro impiego in conformità della nostra  
Cookie Policy.